Harmer, VictoriaAmmendolea, CathyRyan, MandyBoyle, FrancesWerutsky, GustavoEl Mouzain, DinaMarshall, Deborah A.Thomas, CaitlinHeidenreich, SebastianLu, HuiKrucien, NicolasPayan, Juan MoraAubel, DawnDanyliv, AndriyPathak, PurnimaHarbeck, Nadia2025-02-032025-02-032025-01Harmer, V, Ammendolea, C, Ryan, M, Boyle, F, Werutsky, G, El Mouzain, D, Marshall, D A, Thomas, C, Heidenreich, S, Lu, H, Krucien, N, Payan, J M, Aubel, D, Danyliv, A, Pathak, P & Harbeck, N 2025, 'Patient Preferences for HR+/HER2‒ Early Breast Cancer Adjuvant Treatment : A Multicountry Discrete Choice Experiment', Breast Care, vol. 20, no. 1, pp. 16-26. https://doi.org/10.1159/0005433201661-3791https://hdl.handle.net/2164/24979A multicountry steering committee of 8 members – including clinicians, patient representatives, and experts on preference methods – advised on the study design and provided feedback to develop and refine the DCE. We thank the patients who participated. We also thank Harrison Clarke and Ashley Samuelson for their work on the study. Medical writing was provided by Dr. Jacqueline Janowich Wasserott (Evidera) and funded by Novartis.10784497engSDG 3 - Good Health and Well-beingCDK4/6 inhibitorpatient preferencediscrete choice experimentadjuvant treatmentearly breast cancerR MedicineSupplementary InformationSupplementary DataDASRJournal article10.1159/000543320201